409 related articles for article (PubMed ID: 30726572)
1. Enhanced striatopallidal gamma-aminobutyric acid (GABA)
Perez-Rosello T; Gelman S; Tombaugh G; Cachope R; Beaumont V; Surmeier DJ
Mov Disord; 2019 May; 34(5):684-696. PubMed ID: 30726572
[TBL] [Abstract][Full Text] [Related]
2. Striatal Direct and Indirect Pathway Output Structures Are Differentially Altered in Mouse Models of Huntington's Disease.
Barry J; Akopian G; Cepeda C; Levine MS
J Neurosci; 2018 May; 38(20):4678-4694. PubMed ID: 29691329
[TBL] [Abstract][Full Text] [Related]
3. Early GABAergic transmission defects in the external globus pallidus and rest/activity rhythm alteration in a mouse model of Huntington's disease.
Du Z; Chazalon M; Bestaven E; Leste-Lasserre T; Baufreton J; Cazalets JR; Cho YH; Garret M
Neuroscience; 2016 Aug; 329():363-79. PubMed ID: 27217211
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms underlying the enhancement of γ-aminobutyric acid responses in the external globus pallidus of R6/2 Huntington's disease model mice.
Barry J; Sarafian TA; Watson JB; Cepeda C; Levine MS
J Neurosci Res; 2020 Nov; 98(11):2349-2356. PubMed ID: 32856336
[TBL] [Abstract][Full Text] [Related]
5. Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3.
Wójtowicz AM; Dvorzhak A; Semtner M; Grantyn R
Front Neural Circuits; 2013; 7():188. PubMed ID: 24324407
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of the Basal Ganglia Indirect Pathway in Early Symptomatic
Callahan JW; Wokosin DL; Bevan MD
J Neurosci; 2022 Mar; 42(10):2080-2102. PubMed ID: 35058372
[TBL] [Abstract][Full Text] [Related]
7. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.
Centonze D; Rossi S; Prosperetti C; Tscherter A; Bernardi G; Maccarrone M; Calabresi P
Biol Psychiatry; 2005 Jun; 57(12):1583-9. PubMed ID: 15953496
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
Allen KL; Waldvogel HJ; Glass M; Faull RL
J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
[TBL] [Abstract][Full Text] [Related]
9. Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse.
Engler B; Freiman I; Urbanski M; Szabo B
J Pharmacol Exp Ther; 2006 Feb; 316(2):608-17. PubMed ID: 16214880
[TBL] [Abstract][Full Text] [Related]
10. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF.
Cepeda C; Starling AJ; Wu N; Nguyen OK; Uzgil B; Soda T; André VM; Ariano MA; Levine MS
J Neurosci Res; 2004 Dec; 78(6):855-67. PubMed ID: 15505789
[TBL] [Abstract][Full Text] [Related]
11. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.
Farrar AM; Callahan JW; Abercrombie ED
Exp Neurol; 2011 Dec; 232(2):119-25. PubMed ID: 21864528
[TBL] [Abstract][Full Text] [Related]
12. Cholinergic deficits selectively boost cortical intratelencephalic control of striatum in male Huntington's disease model mice.
Pancani T; Day M; Tkatch T; Wokosin DL; González-Rodríguez P; Kondapalli J; Xie Z; Chen Y; Beaumont V; Surmeier DJ
Nat Commun; 2023 Mar; 14(1):1398. PubMed ID: 36914640
[TBL] [Abstract][Full Text] [Related]
13. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease.
Cummings DM; Cepeda C; Levine MS
ASN Neuro; 2010 Jun; 2(3):e00036. PubMed ID: 20585470
[TBL] [Abstract][Full Text] [Related]
14. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists.
Mori A; Shindou T
Neurology; 2003 Dec; 61(11 Suppl 6):S44-8. PubMed ID: 14663009
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Na
Hsu YT; Chang YG; Liu YC; Wang KY; Chen HM; Lee DJ; Yang SS; Tsai CH; Lien CC; Chern Y
Mov Disord; 2019 Jun; 34(6):845-857. PubMed ID: 30840784
[TBL] [Abstract][Full Text] [Related]
16. Major Contribution of Somatostatin-Expressing Interneurons and Cannabinoid Receptors to Increased GABA Synaptic Activity in the Striatum of Huntington's Disease Mice.
Holley SM; Galvan L; Kamdjou T; Dong A; Levine MS; Cepeda C
Front Synaptic Neurosci; 2019; 11():14. PubMed ID: 31139071
[TBL] [Abstract][Full Text] [Related]
17. Differential changes in striatal projection neurons in R6/2 transgenic mice for Huntington's disease.
Sun Z; Del Mar N; Meade C; Goldowitz D; Reiner A
Neurobiol Dis; 2002 Dec; 11(3):369-85. PubMed ID: 12586547
[TBL] [Abstract][Full Text] [Related]
18. Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease.
Indersmitten T; Tran CH; Cepeda C; Levine MS
J Neurophysiol; 2015 Apr; 113(7):2953-66. PubMed ID: 25673747
[TBL] [Abstract][Full Text] [Related]
19. GABA(B) and group I metabotropic glutamate receptors in the striatopallidal complex in primates.
Smith Y; Charara A; Hanson JE; Paquet M; Levey AI
J Anat; 2000 May; 196 ( Pt 4)(Pt 4):555-76. PubMed ID: 10923987
[TBL] [Abstract][Full Text] [Related]
20. HttQ111/+ Huntington's Disease Knock-in Mice Exhibit Brain Region-Specific Morphological Changes and Synaptic Dysfunction.
Kovalenko M; Milnerwood A; Giordano J; St Claire J; Guide JR; Stromberg M; Gillis T; Sapp E; DiFiglia M; MacDonald ME; Carroll JB; Lee JM; Tappan S; Raymond L; Wheeler VC
J Huntingtons Dis; 2018; 7(1):17-33. PubMed ID: 29480209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
